Assessing cognitive impairment in young adults after ischemic stroke

Trajectories of Neurocognitive Impairment After Ischemic Stroke in Young Subjects

This study is testing how an ischemic stroke affects thinking and memory in young adults aged 18-45 over time.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 16 (estimated)
• Ages: 18 Years to 45 Years
• Sex: All
• Sponsor: Centre Hospitalier Universitaire de Nice (other)
• Locations: 2 sites (Cannes and 1 other locations)
• Trial ID: NCT06262529 on ClinicalTrials.gov

What this trial studies

This study focuses on young adults aged 18-45 who have experienced an ischemic stroke, a condition affecting a significant number of individuals in France. It aims to evaluate the prevalence and evolution of cognitive impairment in these patients over time through comprehensive neuropsychological assessments and functional evaluations. By conducting repeated assessments, the study seeks to provide valuable longitudinal data on neurocognitive trajectories in this demographic, which is currently lacking in the literature.

Who should consider this trial

Good fit: Ideal candidates for this study are young adults aged 18 to 45 who have been diagnosed with an ischemic stroke.

Not a fit: Patients with pre-existing cognitive impairments or severe functional dependence prior to the stroke may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of cognitive impairments in young stroke survivors.

How similar studies have performed: While studies on post-stroke cognition exist, this specific focus on young adults with ischemic stroke and their neurocognitive trajectories is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Age: 18 to 45 years.
* Pathology: ischemic stroke diagnosed with brain MRI as per standard clinical practice, with or without occlusion of proximal artery, anterior or posterior circulation.
* Ability to understand and complete study tests and questionnaires: fluent French speaker and reader.
* All patients must be affiliated to a social security scheme.
* Signature of informed consent form.

Exclusion Criteria:

* Pre-existing cognitive impairment (defined as CQI \<78 or clinical dementia).
* Severe functional dependence prior to stroke (defined as Modified Rankin Scale MRS = score 5).
* Any neurological or psychiatric comorbidity.
* Sensory disorders: visual impairment, blindness, deafness.
* Severe acquired phasic disorders: on the expressive oral side, in the presence of an inability to express oneself, which interferes with the collection of responses to neuropsychological tests; and on the receptive oral side, in the presence of an inability to understand the instructions of neuropsychological tests. Phasic functioning is systematically assessed during hospitalization by means of the NIHSS (score ≤ 2 on the "Language" sub-test), and will be rechecked clinically and psychometrically during neuropsychological assessments using the Language Screening Test (LAST) for both expression and oral comprehension. - Severe motor disorders: inability to mobilize the dominant upper limb for written neuropsychological tests.
* Contraindication to MRI.
* Pregnant women.
* HIV-positive patients: interaction of infectious pathology on cognitive functioning. Declarative, no HIV tests will be performed.
* Withdrawal of informed consent.
* Consumption of alcohol and/or narcotics on the day of neuropsychological assessments.

Where this trial is running

Cannes and 1 other locations

• cannes Hospital — Cannes, France (NOT_YET_RECRUITING)
• Nice University Hospital — Nice, France (RECRUITING)

Study contacts

• Study coordinator: Marina PASSALBONI

Conditions: Acute Ischemic Stroke